D. Poole

发表

Generation and characterization of B72.3 second generation monoclonal antibodies reactive with the tumor-associated glycoprotein 72 antigen.

M. Kuroki, A. Thor, J. Schlom, 1988, Cancer research.

New gene expressed in prostate: a potential target for T cell-mediated prostate cancer immunotherapy

James L. Gulley, Ira Pastan, I. Pastan, 2009, Cancer Immunology, Immunotherapy.

A CDR-grafted (humanized) domain-deleted antitumor antibody.

P. Hand, J. Schlom, D. Milenic, 1997, Cancer biotherapy & radiopharmaceuticals.

Pilot Study of Vaccination with Recombinant CEA-MUC-1-TRICOM Poxviral-Based Vaccines in Patients with Metastatic Carcinoma

S. Steinberg, J. Schlom, W. Dahut, 2008, Clinical Cancer Research.

Effect of talactoferrin alfa on the immune system in adults with non-small cell lung cancer.

G. Giaccone, J. Schlom, R. Madan, 2013, The oncologist.

General keynote: vaccine strategies for the therapy of ovarian cancer.

J. Schlom, D. Poole, K. Tsang, 2003, Gynecologic oncology.

Serological mapping of the TAG-72 tumor-associated antigen using 19 distinct monoclonal antibodies.

M. Kuroki, J. Schlom, J. Simpson, 1990, Cancer research.

Phase I study of a vaccine using recombinant vaccinia virus expressing PSA (rV‐PSA) in patients with metastatic androgen‐independent prostate cancer

S. Steinberg, A. Chen, J. Schlom, 2002, The Prostate.

Vaccine therapy of established tumors in the absence of autoimmunity.

J. Schlom, D. Poole, D. Grosenbach, 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial.

S. Steinberg, H. Parnes, J. Schlom, 2012, The Lancet. Oncology.

Modified vaccinia virus ankara recombinants are as potent as vaccinia recombinants in diversified prime and boost vaccine regimens to elicit therapeutic antitumor responses.

J. Schlom, L. Gritz, D. Poole, 2003, Cancer research.

A Pilot Study of MUC-1/CEA/TRICOM Poxviral-Based Vaccine in Patients with Metastatic Breast and Ovarian Cancer

S. Steinberg, J. Schlom, R. Madan, 2011, Clinical Cancer Research.

Clinical safety of a viral vector based prostate cancer vaccine strategy.

S. Steinberg, H. Parnes, J. Schlom, 2007, The Journal of urology.

Evaluation of human carcinoembryonic-antigen (CEA)-transduced and non-transduced murine tumors as potential targets for anti-CEA therapies

P. Hand, J. Schlom, M. Salgaller, 2005, Cancer Immunology, Immunotherapy.

Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer

S. Steinberg, H. Parnes, J. Schlom, 2010, Cancer Immunology, Immunotherapy.

Baculovirus recombinants expressing the human carcinoembryonic antigen gene.

J. Schlom, M. Salgaller, P. Robbins, 1993, Cancer research.

The use of a rapid ELISPOT assay to analyze peptide-specific immune responses in carcinoma patients to peptide vs. recombinant poxvirus vaccines

S. Steinberg, A. Chen, J. Marshall, 2000, Cancer Immunology, Immunotherapy.

Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial.

S. Steinberg, H. Parnes, J. Schlom, 2012, The Lancet. Oncology.